
price close busi april
biomed devic servic
near-term growth overhang expand wait bit
dust settl target
bottom line think fda decis order remov surgic mesh product
market contribut overhang common think could last
back half year maintain buy rate favor bsx
broad growth portfolio long-term oper margin leverag potenti unencumb
balanc sheet think team execut accret deal prefer
new money go current top large-cap stock pick edward lifesci ew
nyse buy nasdaq buy
revenu impact mesh abolit ww annual exacerb
near-term growth impact busi heel issu surround paclitaxel-
coat devic stent balloon peripher intervent competit
win tavr vi -- vi low-risk data ew present march see
note consequ near term think stock could range-bound until/
unless firm demonstr result track ahead guidance/
expect would indic firm myriad growth vector off-set
aforement issu wit modestli reduc revenu ep
estim result reduct year-end target price
regard aforement low-risk tavr data neg impact stock
time believ data serv expand perhap even acceler
tavr market think success captur share upon lotu edg
approv later year initi high/intermediate-risk patient longer term
across full risk spectrum behind three product offer lotu edg accur
sentinel longer term think firm deliv increasingli strong free cash
flow expect manag reiter june
analyst meet ny liabil tax mesh larg rearview mirror look
continu recent trend growth recent deal name augmenix
rezum among other bullish inject addit growth engin
busi think manag leverag exist oper
infrastructur expand margin gross oper drive low teen ep compound-annual-growth-rate
least next year estim said given near-term dynamics/
overhang would wait better entri point albeit maintain buy rate long-
fda order remov surgic mesh product market yesterday fda
issu releas order manufactur surgic mesh product indic
transvagin repair pelvic organ prolaps pop discontinu sale us
immedi total world-wide mesh product sale today make
firm annual revenu yesterday fda decis impact two product
uphold vagin support xenform soft tissu repair
combin world-wide annual revenu repres portion bsx total
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
mesh histor context bsx current posit yesterday decis
stem fda reclassif surgic mesh transvagin repair
pop class ii class medic devic compani wish
continu market mesh product requir submit pma applic
file two pma uphold xenform base
takeaway recent feb fda advisori panel fda determin data
present suffici demonstr devic safeti efficaci requir
hit pma standard result yesterday issu decis separ wed note
settl outstand prior mesh claim
liabil larg behind firm
current statu paclitaxel front decemb meta-analysi
public jaha spur initi flurri dcb/de field recent
develop name fda recent dear-doc letter publish mid-march
advis clinician util altern drug-elut platform current
data better understood widespread longer-last
impact field view specif recent market dynam
remov eluvia ranger firm list growth driver least
near term field grappl work current
data expect continu see data analys releas ahead june fda
preview schedul report number next wednesday april
bmo current model total sale street
wed specif focus updat lotu launch timelin
firm recent state expect commenc limit launch europ
march fda approv expect earli beyond lotu expect
firm deliv anoth strong neuro perform model y/i growth
view firm well posit continu experi strong
adopt wavewrit platform recent db direct lead
approv provid boost tailwind neuro franchis enter
help off-set impact challeng comp watchman view
multipl tailwind across busi expect growth current
account remain strong firm increasingli benefit throughout
recent launch next-gen watchman flx platform europ
upcom market entri japan follow anticip receipt
reimburs region uro pelvic health notwithstand yesterday
fda decis view posit recent trend across portfolio well posit
continu potenti acceler upcom rezum sale
benefit recent code effect bsx recent
close acquisit augmenix scale bsx umbrella
guidanc manag anticip total report sale growth
rang organ revenu growth expect rang
exclud approxim expect contribut recent acquisit
nxthera claret augmenix fx expect headwind
adjust ep anticip rang y/i
buy unchang target price april
biomed devic servic
price target support rel valuat analysi
buy unchang target price april
biomed devic servic
p/e/g valuat financi metric use current mean ex-outli large-cap medic devic price-to-earnings multipl ex outlier large-cap med-tech comp group ep compound-annual-growth-rate forward impli oper incom growth pro forma forward compound-annual-growth-rate p/e/g multipl price-to-earnings multipl forma mo figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price april
biomed devic servic
million except per share expensessel gener oper incom pro expens tax ex charg incom ep excl charg ep variablescost gener oper tax analysisgross profit margin exclud ratestot revenu excl figur revenu model
buy unchang target price april
biomed devic servic
divisioncardiovascularintervent cardiologybare-met stentsd coronari stent bms/de structur heart intervent intervent peripher intervent manag total pacemak rhythm manag revenu currenc revenu oper figur revenu model
buy unchang target price april
biomed devic servic
buy unchang target price april
biomed devic servic
buy unchang target price april
biomed devic servic
edward lifesci implant averag implant total unit asp ew us revenu averag total unit asp total us revenu averag total unit asp us revenu player us revenu us implant address patient penetr us tavr market figur ww tavr model
buy unchang target price april
biomed devic servic
edward lifesci averag implant center total unit total ew ww tavi revenu ex growth averag total unit total ww tavi revenu growth averag total unit total ww tavi revenu growth player ww tavi revenu ww implant target patient popul player tavi ww revenu market figur laa model
buy unchang target price april
biomed devic servic
 implant implant per month per implant per watchman initi indic see market penetr watchman revenu ou implant implant per month per implant per watchman revenu ww watchman
